{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:10:39Z","timestamp":1790723439701,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.micpath.2026.108845","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:56:27Z","timestamp":1790610987000},"page":"108845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Redefining leishmaniasis therapy: Innovations in drug discovery and vaccine design"],"prefix":"10.1016","volume":"221","author":[{"given":"Swati","family":"Pal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7560-4998","authenticated-orcid":false,"given":"Ravinder","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2026.108845_bib1","series-title":"Concepts in Animal Parasitology, Zea Books","first-page":"182","article-title":"Leishmania (Genus) and leishmaniasis","author":"McDowell","year":"2024"},{"key":"10.1016\/j.micpath.2026.108845_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/vms3.1580","article-title":"The complexities of blood-feeding patterns in mosquitoes and sandflies and the burden of disease: a minireview","volume":"10","author":"Bursali","year":"2024","journal-title":"Vet. Med. Sci."},{"key":"10.1016\/j.micpath.2026.108845_bib54","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.1021\/acs.jmedchem.0c00499","article-title":"Discovery and characterization of clinical candidate LXE408 as a kinetoplastid-selective proteasome inhibitor for the treatment of leishmaniases","volume":"63","author":"Nagle","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.micpath.2026.108845_bib56","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00477-24","article-title":"CRISPR-Cas9 high-throughput screening to study drug resistance in Leishmania infantum","volume":"15","author":"Queffeulou","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.micpath.2026.108845_bib60","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1073\/pnas.1820175116","article-title":"Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition","volume":"116","author":"Wyllie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.micpath.2026.108845_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0014181","article-title":"Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: a Phase 1, randomized, single ascending dose escalation study in healthy participants","volume":"20","author":"Moodley","year":"2026","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.micpath.2026.108845_bib57","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1021\/acs.jmedchem.8b01218","article-title":"Identification of GSK3186899\/DDD853651 as a preclinical development candidate for the treatment of visceral leishmaniasis","volume":"62","author":"Thomas","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.micpath.2026.108845_bib58","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70535","article-title":"Translational pharmacokinetic-pharmacodynamic modeling and efficacious human dose prediction of DNDI-6148 for the treatment of cutaneous leishmaniasis","volume":"19","author":"Henninger","year":"2026","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.micpath.2026.108845_bib59","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/bcp.70328","article-title":"Safety, tolerability and pharmacokinetics of DNDI-6148, a novel agent for leishmaniasis: a randomized, controlled, single ascending dose study in healthy participants","volume":"92","author":"Gillon","year":"2026","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.micpath.2026.108845_bib62","article-title":"PF-429242, a subtilisin inhibitor, is effective in vitro against Leishmania infantum","volume":"12","author":"de Almeida Machado","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2026.108845_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh9902","article-title":"DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1","volume":"15","author":"Braillard","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.micpath.2026.108845_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-53762-3","article-title":"Synthesis and anti-antileishmanial profile of novel thiazolidine-4-one derivatives and molecular docking and molecular dynamics simulations studies","volume":"16","author":"Molaei","year":"2026","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2026.108845_bib65","doi-asserted-by":"crossref","DOI":"10.1155\/tbed\/9050245","article-title":"Eprinomectin inhibits Leishmania by inducing mitochondrial dysfunction and cell cycle arrest","author":"Yu","year":"2026","journal-title":"Transbound. Emerg. Dis."},{"key":"10.1016\/j.micpath.2026.108845_bib66","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/1873-3468.15016","article-title":"Identification of novel anti-leishmanials targeting glutathione synthetase of the parasite: a drug repurposing approach","volume":"599","author":"Sarma","year":"2025","journal-title":"FEBS Lett."},{"key":"10.1016\/j.micpath.2026.108845_bib67","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1021\/acsmedchemlett.6c00201","article-title":"Systems-driven identification and experimental validation of actinomycetes-derived secondary metabolites as promising antileishmanial agents targeting Leishmania donovani methionyl-tRNA synthetase","volume":"17","author":"Singh","year":"2026","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.micpath.2026.108845_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2024.107143","article-title":"Quinine and chloroquine: potential preclinical candidates for the treatment of tegumentary leishmaniasis","volume":"252","author":"Rossi","year":"2024","journal-title":"Acta Trop."},{"key":"10.1016\/j.micpath.2026.108845_bib69","doi-asserted-by":"crossref","first-page":"200","DOI":"10.12688\/wellcomeopenres.17951.1","article-title":"LEISH2b: a phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis","volume":"7","author":"Lacey","year":"2022","journal-title":"Wellcome Open Res."},{"key":"10.1016\/j.micpath.2026.108845_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295495","article-title":"Designing of a new multi-epitope vaccine against Leishmania major using Leish-F1 epitopes: an in-silico study","volume":"19","author":"Rabienia","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2026.108845_bib71","doi-asserted-by":"crossref","first-page":"323","DOI":"10.25259\/IJMR_1040_2024","article-title":"An update on recombinant vaccines against leishmaniasis","volume":"160","author":"Shital","year":"2024","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.micpath.2026.108845_bib72","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.micpath.2026.108845_bib73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41541-025-01070-8","article-title":"LmCen\u2212\/\u2212 based vaccine is protective against canine visceral leishmaniasis following three natural exposures in Tunisia","volume":"10","author":"Boussoffara","year":"2025","journal-title":"npj Vaccines"},{"key":"10.1016\/j.micpath.2026.108845_bib74","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/acsptsci.4c00341","article-title":"Molecular and immunological properties of a chimeric glycosyl hydrolase 18 based on immunoinformatics approaches: a design of a new Anti-Leishmania vaccine","volume":"8","author":"da Cruz Freire","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.micpath.2026.108845_bib75","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/infdis\/jiae526","article-title":"CpG-adjuvanted virus-like particle vaccine induces protective immunity against Leishmania donovani infection","volume":"231","author":"Yoon","year":"2025","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.micpath.2026.108845_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012707","article-title":"Large-scale randomized double-blind field clinical trial for safety and efficacy assessment of the DNA vaccine Neoleish against canine leishmaniasis","volume":"19","author":"P\u00e1ez","year":"2025","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.micpath.2026.108845_bib77","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13071-025-06756-5","article-title":"Screening helper T lymphocyte epitopes based on IFN-\u03b3\/IL-10 ratio for developing a novel multi-epitope vaccine candidate using Wolbachia surface protein as an adjuvant against visceral leishmaniasis","volume":"18","author":"Zhang","year":"2025","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.micpath.2026.108845_bib78","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1007\/s10528-026-11336-y","article-title":"Leish-F1 multi-epitope lentiviral vaccine as a novel candidate against Leishmania major in Balb\/c mice","volume":"64","author":"Daneshi","year":"2026","journal-title":"Biochem. Genet."},{"key":"10.1016\/j.micpath.2026.108845_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156475","article-title":"Interleukin-7 potentiates MAPK10-elicited host-protective vaccine against Leishmania donovani","volume":"174","author":"Kumar","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/j.micpath.2026.108845_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112538","article-title":"PLGA nanoparticle-delivered Leishmania antigen and TLR agonists as a therapeutic vaccine against cutaneous leishmaniasis in BALB\/c mice","volume":"138","author":"Katebi","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.micpath.2026.108845_bib3","first-page":"601","article-title":"Cutaneous and mucocutaneous leishmaniasis","volume":"112","author":"Diago","year":"2021","journal-title":"Actas Dermo-Sifiliogr. (Engl. Ed.)"},{"key":"10.1016\/j.micpath.2026.108845_bib4","series-title":"Hair in Infectious Disease: Recognition, Treatment, and Prevention","first-page":"197","article-title":"Tropical diseases","author":"Gavazzoni Dias","year":"2023"},{"key":"10.1016\/j.micpath.2026.108845_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.707619","article-title":"Precision medicine in control of visceral leishmaniasis caused by L. donovani","volume":"11","author":"Zijlstra","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.micpath.2026.108845_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/pathogens13060455","article-title":"Global distribution of canine visceral leishmaniasis and the role of the dog in the epidemiology of the disease","volume":"13","author":"Vilas-Boas","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.micpath.2026.108845_bib7","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1016\/S1473-3099(16)30140-2","article-title":"Elimination of visceral leishmaniasis on the Indian subcontinent","volume":"16","author":"Singh","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2026.108845_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007831","article-title":"The importance of vector control for the control and elimination of vector-borne diseases","volume":"14","author":"Wilson","year":"2020","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.micpath.2026.108845_bib9","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1111\/jdv.16333","article-title":"Evidence supporting the enhanced efficacy of pentavalent antimonials with adjuvant therapy for cutaneous leishmaniasis: a systematic review and meta-analysis","volume":"34","author":"Husein-ElAhmed","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.micpath.2026.108845_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012127","article-title":"Local amphotericin B therapy for Cutaneous Leishmaniasis: a systematic review","volume":"18","author":"Alves","year":"2024","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.micpath.2026.108845_bib11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/17460441.2020.1743674","article-title":"The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history","volume":"15","author":"Reim\u00e3o","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.micpath.2026.108845_bib12","article-title":"Progress in antileishmanial drugs: mechanisms, challenges, and prospects","volume":"19","author":"Zhang","year":"2025","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.micpath.2026.108845_bib13","series-title":"Combination Therapy Against Multidrug Resistance","first-page":"1","article-title":"Combination therapy: current status and future perspectives","author":"Malik","year":"2020"},{"key":"10.1016\/j.micpath.2026.108845_bib14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1017\/S0031182025101522","article-title":"Leishmaniasis vaccine research: current status and new directions","volume":"153","author":"Topuz Ata","year":"2026","journal-title":"Parasitology"},{"key":"10.1016\/j.micpath.2026.108845_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/vaccines14010054","article-title":"An overview of the factors related to Leishmania vaccine development","volume":"14","author":"Passero","year":"2026","journal-title":"Vaccines"},{"key":"10.1016\/j.micpath.2026.108845_bib16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/21645515.2019.1678998","article-title":"Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis","volume":"16","author":"Coutinho De Oliveira","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.micpath.2026.108845_bib17","series-title":"Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges: Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis","first-page":"307","article-title":"Vaccine development for human leishmaniasis","author":"de Carvalho Cl\u00edmaco","year":"2023"},{"key":"10.1016\/j.micpath.2026.108845_bib18","series-title":"Challenges and Solutions Against Visceral Leishmaniasis","first-page":"325","article-title":"Toward a safe and efficacious pan-leishmania vaccine","author":"Bhattacharya","year":"2024"},{"key":"10.1016\/j.micpath.2026.108845_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/pim.70006","article-title":"How effective are the canine visceral leishmaniasis vaccines currently being tested in dogs? A systematic review and meta-analysis","volume":"47","author":"de P\u00e1dua","year":"2025","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.micpath.2026.108845_bib20","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3390\/pathogens14100970","article-title":"Overview of commercial vaccines against canine visceral leishmaniasis: current landscape and future directions","volume":"14","author":"Martiniano de P\u00e1dua","year":"2025","journal-title":"Pathogens"},{"key":"10.1016\/j.micpath.2026.108845_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006571","article-title":"Combining epidemiology with basic biology of sand flies, parasites, and hosts to inform leishmaniasis transmission dynamics and control","volume":"13","author":"Courtenay","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.micpath.2026.108845_bib22","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.drudis.2017.06.004","article-title":"Leishmaniasis drug discovery: recent progress and challenges in assay development","volume":"22","author":"Zulfiqar","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.micpath.2026.108845_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174436","article-title":"Advancement in leishmaniasis diagnosis and therapeutics: an update","volume":"910","author":"Kumari","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.micpath.2026.108845_bib24","article-title":"Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function","volume":"11","author":"Botero Aguirre","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.micpath.2026.108845_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taab065","article-title":"Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review","volume":"28","author":"Piccica","year":"2021","journal-title":"J. Trav. Med."},{"key":"10.1016\/j.micpath.2026.108845_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106459","article-title":"An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis","volume":"59","author":"Pali\u0107","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.micpath.2026.108845_bib27","article-title":"A review of current treatments strategies based on paromomycin for leishmaniasis","volume":"57","author":"Matos","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.micpath.2026.108845_bib28","first-page":"2121","article-title":"Antileishmanial activity of itraconazole (Sporanox\u00ae) and fluconazole (Zoltec\u00ae) on Leishmania spp.: in silico and in vitro studies for repurposing drugs","volume":"43","author":"dos Santos","year":"2024","journal-title":"Lat. Am. J. Pharm."},{"key":"10.1016\/j.micpath.2026.108845_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009099","article-title":"Therapeutic advances in the topical treatment of cutaneous leishmaniasis: a review","volume":"15","author":"Azim","year":"2021","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.micpath.2026.108845_bib30","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3390\/pathogens13090812","article-title":"Advances in Leishmania vaccines: current development and future prospects","volume":"13","author":"Ayala","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.micpath.2026.108845_bib31","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1017\/S0031182024001240","article-title":"Preclinical evaluation of immunogenicity and protective efficacy of a recombinant chimeric protein vaccine against visceral leishmaniasis","volume":"152","author":"Lage","year":"2025","journal-title":"Parasitology"},{"key":"10.1016\/j.micpath.2026.108845_bib32","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.ymthe.2021.03.020","article-title":"Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan","volume":"29","author":"Younis","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.micpath.2026.108845_bib33","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fimmu.2020.00204","article-title":"The delay in the licensing of protozoal vaccines: a comparative history","volume":"11","author":"Palatnik-de-Sousa","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108845_bib34","doi-asserted-by":"crossref","first-page":"6695","DOI":"10.1016\/j.vaccine.2020.08.051","article-title":"Immunoprophylaxis pharmacotherapy against canine leishmaniosis: a systematic review and meta-analysis on the efficacy of vaccines approved in European Union","volume":"38","author":"Calzetta","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2026.108845_bib35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/vde.70006","article-title":"World Association for veterinary dermatology consensus statement for diagnosis, and Evidence-based clinical practice guidelines for treatment and prevention of canine leishmaniosis","volume":"36","author":"Saridomichelakis","year":"2025","journal-title":"Vet. Dermatol."},{"key":"10.1016\/j.micpath.2026.108845_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.cimid.2023.101984","article-title":"Live attenuated Leishmania infantum centrin deleted mutant (LiCen\u2212\/\u2212) as a novel vaccine candidate: a field study on safety, immunogenicity, and efficacy against canine leishmaniasis","author":"Zarei","year":"2023","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"10.1016\/j.micpath.2026.108845_bib37","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s42003-021-02446-x","article-title":"Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis","volume":"4","author":"Karmakar","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.micpath.2026.108845_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2025.107796","article-title":"Advances in recombinant protein vaccines against Leishmania infantum: a systematic review of vaccinal constructs and delivery strategies","volume":"270","author":"Martins","year":"2025","journal-title":"Acta Trop."},{"key":"10.1016\/j.micpath.2026.108845_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012757","article-title":"Efficacy of vaccines based on chimeric or multiepitope antigens for protection against visceral leishmaniasis: a systematic review","volume":"18","author":"Lopes","year":"2024","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.micpath.2026.108845_bib41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12951-025-03201-8","article-title":"The immunogenic potential of an optimized mRNA lipid nanoparticle formulation carrying sequences from virus and protozoan antigens","volume":"23","author":"Fernandes","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.micpath.2026.108845_bib42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41541-025-01213-x","article-title":"IL-12 mRNA-LNP promotes dermal resident memory CD4+ T cell development","volume":"10","author":"Zabala-Pe\u00f1afiel","year":"2025","journal-title":"npj Vaccines"},{"key":"10.1016\/j.micpath.2026.108845_bib43","article-title":"Leishmania vaccine development: a comprehensive review","volume":"399\u2013400","author":"Saini","year":"2024","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.micpath.2026.108845_bib44","doi-asserted-by":"crossref","DOI":"10.2174\/0115701638291767240513113400","article-title":"Vaccine designing technology against leishmaniasis: current challenges and implication","volume":"22","author":"Gupta","year":"2025","journal-title":"Curr. Drug Discov. Technol."},{"key":"10.1016\/j.micpath.2026.108845_bib45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13071-025-07188-x","article-title":"Concomitant immunity in persistent Leishmania infections: could it represent an evolutionary balance and a vaccine target?","volume":"19","author":"Divenuto","year":"2026","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.micpath.2026.108845_bib46","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/14760584.2021.1990043","article-title":"Overcoming roadblocks in the development of vaccines for leishmaniasis","volume":"20","author":"Kaye","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.micpath.2026.108845_bib47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fimmu.2014.00241","article-title":"Biomarkers of safety and immune protection for genetically modified live attenuated Leishmania vaccines against visceral leishmaniasis-discovery and implications","volume":"5","author":"Gannavaram","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108845_bib48","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1038\/s41591-024-03146-9","article-title":"Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis","volume":"30","author":"Parkash","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.micpath.2026.108845_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70160","article-title":"Harnessing controlled human infection models to accelerate vaccine development for neglected tropical diseases: lessons from leishmaniasis","volume":"56","author":"Parkash","year":"2026","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.micpath.2026.108845_bib50","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1021\/acsinfecdis.4c00010","article-title":"Revolutionizing leishmaniasis treatment with cutting edge drug delivery systems and nanovaccines: an updated review","volume":"10","author":"Tambe","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.micpath.2026.108845_bib51","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/14760584.2021.1991795","article-title":"Vaccines against leishmaniasis: using controlled human infection models to accelerate development","volume":"20","author":"Parkash","year":"2021","journal-title":"Expert Rev. Vaccines"},{"issue":"1","key":"10.1016\/j.micpath.2026.108845_bib52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41467-020-20569-3","article-title":"Characterization of a new Leishmania major strain for use in a controlled human infection model","volume":"12","author":"Ashwin","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2026.108845_bib53","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/14760584.2021.1969231","article-title":"From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection","volume":"20","author":"Volpedo","year":"2021","journal-title":"Expert Rev. Vaccines"}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401026005711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401026005711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:40:02Z","timestamp":1790721602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401026005711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":78,"alternative-id":["S0882401026005711"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2026.108845","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redefining leishmaniasis therapy: Innovations in drug discovery and vaccine design","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2026.108845","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108845"}}